BioCryst Pharmaceuticals Earnings: Here’s Why Investors are Not Excited Now

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) had a loss and missed Wall Street’s expectations, AND came up short on beating the revenue expectation. The revenue miss is a negative sign to shareholders seeking high growth out of the company. Shares are down 6.86%.

BioCryst Pharmaceuticals, Inc. Earnings Cheat Sheet

Results: Adjusted Earnings Per Share decreased to $-0.23 in the quarter versus EPS of $-0.25 in the year-earlier quarter.

Revenue: Decreased 80.52% to $820,000 from the year-earlier quarter.

Actual vs. Wall St. Expectations: BioCryst Pharmaceuticals, Inc. reported adjusted EPS loss of $0.23 per share. By that measure, the company missed the mean analyst estimate of $-0.14. It missed the average revenue estimate of $2.01 million.

Quoting Management: “The fact that we met all of our goals for the BCX4161 Phase 1 trial and secured government funding for the peramivir NDA filing represents a significant step forward for BioCryst,” said Jon P. Stonehouse, President & Chief Executive Officer of BioCryst. “We look forward to initiating the BCX4161 Phase 2a clinical trial and to submitting a peramivir NDA by year end. Our very successful recent financing has allowed us to attract additional high quality investors into the company and has provided us the cash runway to carry us into 2015.”

Key Stats (on next page)…

Revenue decreased 76.9% from $3.55 million in the previous quarter. EPS increased to $-0.23 in the quarter versus EPS of $-0.09 in the previous quarter.

Looking Forward: Analysts have a neutral outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings is a loss of $0.11 and has not changed. For the current year, the average estimate has moved down from a loss of $0.46 to a loss of $0.47 over the last ninety days.

Stocks with improving earnings metrics are worthy of your extra attention. In fact, “E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our CHEAT SHEET investing framework for this very reason. Don’t waste another minute – click here and get our CHEAT SHEET stock picks now.

(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at]